Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course.
acromegaly
immunohistochemistry
somatostatin analogues
somatostatin receptor subtype
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
07 Jun 2021
07 Jun 2021
Historique:
received:
10
05
2021
revised:
02
06
2021
accepted:
05
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Somatostatin analogues are considered to be the first line of treatment in acromegaly. Somatostatin analogues of the first generation mainly target the somatostatin receptor (SSTR) subtype 2 and have been proven efficient in the majority of patients with acromegaly. Pasireotide was the first somatostatin analogue also substantially targeting the SSTR subtype 5. An efficient drug for Cushing's disease tailored to suboptimal-responding patients with acromegaly then became available. We immunohistochemically investigated SSTR subtypes expression in pituitary adenomas from operated acromegaly patients with clinical relapse and a complicated clinical course. Patients received pasireotide in the course of their disease. The predictive value of SSTR subtypes immunhistochemical analysis for the therapeutic response is discussed.
Identifiants
pubmed: 34200337
pii: diagnostics11061050
doi: 10.3390/diagnostics11061050
pmc: PMC8228866
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
Neuroendocrinology. 2017;105(1):44-53
pubmed: 27455094
J Clin Endocrinol Metab. 2011 May;96(5):1327-35
pubmed: 21325455
J Clin Endocrinol Metab. 2012 May;97(5):1589-97
pubmed: 22362824
Front Endocrinol (Lausanne). 2018 Mar 07;9:78
pubmed: 29563895
Pituitary. 2015 Jun;18(3):385-94
pubmed: 25103549
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9
pubmed: 24423324
Eur J Endocrinol. 2018 Aug 23;179(5):D15-D25
pubmed: 30139823
J Clin Endocrinol Metab. 2009 Jan;94(1):115-22
pubmed: 18957506
Front Endocrinol (Lausanne). 2019 May 29;10:334
pubmed: 31191457
J Pers Med. 2019 Nov 15;9(4):
pubmed: 31731613
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Biomedicines. 2019 Jan 04;7(1):
pubmed: 30621143
J Clin Endocrinol Metab. 2019 Mar 1;104(3):915-924
pubmed: 30346538
Trends Endocrinol Metab. 2013 May;24(5):238-46
pubmed: 23270713
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84
pubmed: 25260838
Eur J Endocrinol. 2016 Feb;174(2):241-50
pubmed: 26586796